Company intelligence / Profile preview

ScreenSYS

Freiburg im Breisgau, Baden-Württemberg, Germanyscreensys.eu ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

ScreenSYS has developed a proprietary AI-driven automated workflow to generate Doubled Haploid plants from single cells. This enables rapid development of homozygous inbred lines across various crops. The technology has been validated with multiple species and recognized by the German Research Allowance Certification Office (BSFZ) for its high R&D investment. Production facilities are being expanded to serve more breeders directly.

Therapeutic areas: OtherMetabolic DisordersInfectious Diseases
Modalities: Automated cell reprogrammingAI-based phenotypingMicropropagation
Industry: Agriculture & AgTech

Partnerships

Collaborates with plant breeders and agricultural biotech companies globallyPure Group/Puregene AG (for cannabis breeding innovation)

Beyond the preview

Go deeper on ScreenSYS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ScreenSYS.

Explore the full profile